The Full Wiki

More info on Metelimumab

Metelimumab: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Metelimumab ?
Monoclonal antibody
Type whole antibody
Source human
Target TGF beta 1
CAS number 272780-74-2
ATC code none
Chemical data
Formula  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future[1], Metelimumab was dropped from further development in favour of GC-1008[2], which is currently being developed by Genzyme[3].


CAT-192 was isolated by Cambridge Antibody Technology using its phage display technology. In 2000, Cambridge Antibody Technology signed a collaborative deal with Genzyme to further develop TGF beta antibodies[4][5].

In 2004, Cambridge Antibody Technology and Genzyme revealed that Phase I/II trials of CAT-192 for scleroderma showed the human anti-TGF-Beta1 monoclonal antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]

Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of GC-1008[2], which is currently being developed by Genzyme[3].


  1. ^
  2. ^ a b
  3. ^ a b
  4. ^
  5. ^
  6. ^
  7. ^


Got something to say? Make a comment.
Your name
Your email address